Company: PTHS
Filing Date: 2025-04-17
Form Type: 8-K
Source: 0001753926-25-000652
Chunk: 13

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-04-17
Form: 8-K
Item: Item 4.01
Chunk 13
---
 no vulnerabilities in these systems.

Prior to engaging CBIZ, Channel did not
consult with CBIZ regarding the application of accounting principles to a specific completed or contemplated transaction or regarding
the type of audit opinions that might be rendered by CBIZ on Channel’s consolidated financial statements, and CBIZ did not
provide any written or oral advice that was an important factor considered by Channel in reaching a decision as to any such accounting,
auditing, or financial reporting issue.

Channel provided Marcum with a copy of
this Current Report on Form 8-K prior to its filing with the SEC and requested that Marcum furnish Channel with a letter addressed
to the SEC, pursuant to Item 304(a)(3) of Regulation S-K, stating whether it agrees with the above statements and, if it does not
agree, the respects in which it does not agree. A copy of the letter, dated April 17, 2025, is filed as Exhibit 16.1 (which is
incorporated by reference herein) to this Current Report on Form 8-K.

Item 5.07. Submission of Matters to
a Vote of Security Holders

The disclosure set forth above in the paragraph
titled, “ Stockholder Approval of Transaction” in Item 1.01 of this Current Report on Form 8-K is incorporated
by reference into this Item 5.07. Channel intends to file with the SEC, and mail to its stockholders, an information statement
on Schedule 14C describing the Merger Agreement and the transactions contemplated thereby.

Item 7.01. Regulation FD Disclosure